154 related articles for article (PubMed ID: 8896393)
1. Human eosinophils express functional CD30 ligand and stimulate proliferation of a Hodgkin's disease cell line.
Pinto A; Aldinucci D; Gloghini A; Zagonel V; Degan M; Improta S; Juzbasic S; Todesco M; Perin V; Gattei V; Herrmann F; Gruss HJ; Carbone A
Blood; 1996 Nov; 88(9):3299-305. PubMed ID: 8896393
[TBL] [Abstract][Full Text] [Related]
2. The role of eosinophils in the pathobiology of Hodgkin's disease.
Pinto A; Aldinucci D; Gloghini A; Zagonel V; Degan M; Perin V; Todesco M; De Iuliis A; Improta S; Sacco C; Gattei V; Gruss HJ; Carbone A
Ann Oncol; 1997; 8 Suppl 2():89-96. PubMed ID: 9209649
[TBL] [Abstract][Full Text] [Related]
3. CD30 ligand expression in nonmalignant and Hodgkin's disease-involved lymphoid tissues.
Gruss HJ; Pinto A; Gloghini A; Wehnes E; Wright B; Boiani N; Aldinucci D; Gattei V; Zagonel V; Smith CA; Kadin ME; von Schilling C; Goodwin RG; Herrmann F; Carbone A
Am J Pathol; 1996 Aug; 149(2):469-81. PubMed ID: 8701986
[TBL] [Abstract][Full Text] [Related]
4. Mast cells express functional CD30 ligand and are the predominant CD30L-positive cells in Hodgkin's disease.
Molin D; Fischer M; Xiang Z; Larsson U; Harvima I; Venge P; Nilsson K; Sundström C; Enblad G; Nilsson G
Br J Haematol; 2001 Sep; 114(3):616-23. PubMed ID: 11552987
[TBL] [Abstract][Full Text] [Related]
5. CD30 ligand is frequently expressed in human hematopoietic malignancies of myeloid and lymphoid origin.
Gattei V; Degan M; Gloghini A; De Iuliis A; Improta S; Rossi FM; Aldinucci D; Perin V; Serraino D; Babare R; Zagonel V; Gruss HJ; Carbone A; Pinto A
Blood; 1997 Mar; 89(6):2048-59. PubMed ID: 9058727
[TBL] [Abstract][Full Text] [Related]
6. Recombinant CD30 ligand and CD40 ligand share common biological activities on Hodgkin and Reed-Sternberg cells.
Gruss HJ; Ulrich D; Braddy S; Armitage RJ; Dower SK
Eur J Immunol; 1995 Jul; 25(7):2083-9. PubMed ID: 7621881
[TBL] [Abstract][Full Text] [Related]
7. Autocrine growth regulation of CD30 ligand in CD30-expressing Reed-Sternberg cells: distinction between Hodgkin's disease and anaplastic large cell lymphoma.
Hsu PL; Hsu SM
Lab Invest; 2000 Jul; 80(7):1111-9. PubMed ID: 10908157
[TBL] [Abstract][Full Text] [Related]
8. The CD30 ligand and CD40 ligand regulate CD54 surface expression and release of its soluble form by cultured Hodgkin and Reed-Sternberg cells.
Gruss HJ; Scheffrahn I; Hubinger G; Duyster J; Hermann F
Leukemia; 1996 May; 10(5):829-35. PubMed ID: 8656679
[TBL] [Abstract][Full Text] [Related]
9. Protrusion-guided extracellular vesicles mediate CD30 trans-signalling in the microenvironment of Hodgkin's lymphoma.
Hansen HP; Engels HM; Dams M; Paes Leme AF; Pauletti BA; Simhadri VL; Dürkop H; Reiners KS; Barnert S; Engert A; Schubert R; Quondamatteo F; Hallek M; Pogge von Strandmann E
J Pathol; 2014 Mar; 232(4):405-14. PubMed ID: 24659185
[TBL] [Abstract][Full Text] [Related]
10. Expression and regulation of CD30 ligand and CD30 in human leukemia-lymphoma cell lines.
Gruss HJ; DaSilva N; Hu ZB; Uphoff CC; Goodwin RG; Drexler HG
Leukemia; 1994 Dec; 8(12):2083-94. PubMed ID: 7528856
[TBL] [Abstract][Full Text] [Related]
11. CD30 ligand, a member of the TNF ligand superfamily, with growth and activation control CD30+ lymphoid and lymphoma cells.
Gruss H-J ; Herrmann F
Leuk Lymphoma; 1996 Feb; 20(5-6):397-409. PubMed ID: 8833395
[TBL] [Abstract][Full Text] [Related]
12. CD30 ligand in lymphoma patients with CD30+ tumors.
Younes A; Consoli U; Snell V; Clodi K; Kliche KO; Palmer JL; Gruss HJ; Armitage R; Thomas EK; Cabanillas F; Andreeff M
J Clin Oncol; 1997 Nov; 15(11):3355-62. PubMed ID: 9363866
[TBL] [Abstract][Full Text] [Related]
13. Structural and biological features of the TNF receptor and TNF ligand superfamilies: interactive signals in the pathobiology of Hodgkin's disease.
Gruss HJ; Duyster J; Herrmann F
Ann Oncol; 1996; 7 Suppl 4():19-26. PubMed ID: 8836404
[TBL] [Abstract][Full Text] [Related]
14. CD30 ligand signal transduction involves activation of a tyrosine kinase and of mitogen-activated protein kinase in a Hodgkin's lymphoma cell line.
Wendtner CM; Schmitt B; Gruss HJ; Druker BJ; Emmerich B; Goodwin RG; Hallek M
Cancer Res; 1995 Sep; 55(18):4157-61. PubMed ID: 7545087
[TBL] [Abstract][Full Text] [Related]
15. Increased accumulation of CD30 ligand-positive mast cells associates with eosinophilic inflammation in nasal polyps.
Zhai GT; Li JX; Zhang XH; Liao B; Lu X; Liu Z
Laryngoscope; 2019 Mar; 129(3):E110-E117. PubMed ID: 30570137
[TBL] [Abstract][Full Text] [Related]
16. CD30L-ETA': a new recombinant immunotoxin based on the CD30 ligand for possible use against human lymphoma.
Barth S; Matthey B; Huhn M; Diehl V; Engert A
Cytokines Cell Mol Ther; 1999 Jun; 5(2):69-78. PubMed ID: 10515679
[TBL] [Abstract][Full Text] [Related]
17. CD30 ligand (CD30L)-expressing acute myeloid leukemias: a new model of paracrine interactions for the regulation of blast cells proliferation.
Gattei V; Degan M; Rossi FM; de Iuliis A; Mazzocco FT; Serraino D; Zagonel V; Aldinucci D; Pinto A
Leuk Lymphoma; 1999 Sep; 35(1-2):21-35. PubMed ID: 10512160
[TBL] [Abstract][Full Text] [Related]
18. Hodgkin's Disease and Anaplastic Large Cell Lymphoma Revisited. 1. unique cytokine and cytokine receptor profile distinguished from that of non-hodgkin's lymphomas.
Hsu SM; Waldron J; Xie SS; Hsu PL
J Biomed Sci; 1995 Oct; 2(4):302-313. PubMed ID: 11725067
[TBL] [Abstract][Full Text] [Related]
19. Human angiogenin fused to human CD30 ligand (Ang-CD30L) exhibits specific cytotoxicity against CD30-positive lymphoma.
Huhn M; Sasse S; Tur MK; Matthey B; Schinköthe T; Rybak SM; Barth S; Engert A
Cancer Res; 2001 Dec; 61(24):8737-42. PubMed ID: 11751393
[TBL] [Abstract][Full Text] [Related]
20. Expression of functional CD40 antigen on Reed-Sternberg cells and Hodgkin's disease cell lines.
Carbone A; Gloghini A; Gattei V; Aldinucci D; Degan M; De Paoli P; Zagonel V; Pinto A
Blood; 1995 Feb; 85(3):780-9. PubMed ID: 7530508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
